Mineralys Therapeutics, Inc. MLYS
15.61 USD -0.20 (-1.27%)
Nov 10, 2026, 10:53 AM EST
15.26 Day range 16.52
14.91 52-week range 47.65
- YTD
- -56.99%
- 1 year
- -64.92%
- Market cap
- 1.38B
- EPS (ttm)
- -4.30
- Shares out
- 88.56M
- Forward P/E
- -5.95
- YTD return
- -56.99%
- 1-year return
- -64.92%
- Volume
- 220.84K
- Avg volume
- 1.46M
- Open
- 15.48
- Previous close
- 15.81
- Day's range
- 15.26 – 16.52
- 52-week range
- 14.91 – 47.65
- Beta
- 0.82
- Analysts
- Strong Buy
- Price target
- 43.56 (+179.0%)
- Earnings date
- Mar 11, 2027
No chart data for this range yet.
Key statistics
- Enterprise value
- 831.18M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.78
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -210.65M
- Total cash
- 624.67M
- Total debt
- 98.27M
- Return on equity
- -68.50%
- Short % of float
- 10.06%
- 50-day average
- 23.78
- 200-day average
- 26.58
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 43.56 +179.0% upside
Now 15.61
- Target (low)
- 19.00
- Target (mean)
- 43.56
- Target (high)
- 56.00
Ratings (0m) 11 9 buy · 2 hold · 0 sell
- Strong buy0
- Buy9
- Hold2
- Sell0
- Strong sell0
Next earnings
Mar 11, 2027
Expected Mar 11, 2027. Consensus EPS estimate -0.67008.
Financials — quick view
MLYS Revenue — quarterly 0
MLYS Net income — quarterly -57.33M
MLYS EPS — quarterly -0.64
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 11, 2027 | Dec 30, 2026 | -0.63 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.5548 | -0.64 | -0.09 | -15.36% |
| Aug 12, 2026 | Jun 30, 2026 | -0.54857 | -2.85 | -2.30 | -419.53% |
| May 6, 2026 | Mar 31, 2026 | -0.51 | -0.47 | +0.04 | +7.84% |
| Mar 12, 2026 | Dec 31, 2025 | -0.51625 | -0.40 | +0.12 | +22.52% |
| Nov 10, 2025 | Sep 30, 2025 | -0.66 | -0.52 | +0.14 | +21.21% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | UBS | init | — | Neutral |
| Oct 12, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 27, 2026 | TD Cowen | init | — | Buy |
| Mar 13, 2026 | B of A Securities | main | Buy | Buy |
| Dec 19, 2025 | Stifel | main | Buy | Buy |
| Nov 12, 2025 | HC Wainwright & Co. | main | Buy | Buy |
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- mineralystx.com
News
Mineralys: Fairly Valued Near $17 As Baxfendy Launch Validates Slow ASI Ramp (Upgrade) 
What Mineralys Therapeutics (MLYS) Said on Its Q3 Earnings Call 
Mineralys Therapeutics, Inc. (MLYS) Q3 2026 Earnings Call Transcript 
Mineralys Therapeutics Q3 2026 Earnings Call Transcript 
Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update 
Mineralys Therapeutics to Participate in Upcoming Investor Conferences 
Mineralys Therapeutics Announces Phase 2 Explore-CKD Trial Met Its Primary Endpoint; Publishes Full Results In The Journal 'Kidney International' 
UBS Initiates Coverage On Mineralys Therapeutics with Neutral Rating, Announces Price Target of $29 
HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $56 Price Target 
Mineralys Therapeutics Reports New Data Of Analysis From Its Pivotal Phase 3 Launch-HTN Study
Your note
Sign in to keep a note on MLYS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Feb 18, 2026 | 5,877,220 |
| CONGLETON JON | Chief Executive Officer | Sale | Jul 12, 2026 | 603,621 |
| FERGUSON JAMES J. III | Officer | Stock Award(Grant) | Aug 9, 2026 | 102,400 |
| KARYDAS DAPHNE | Director | Conversion of Exercise of derivative security | Sep 14, 2026 | 6,200 |
| LEVY ADAM SCOTT | Chief Financial Officer | Stock Award(Grant) | Feb 18, 2026 | 48,538 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Mar 29, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Catalys Pacific, LLC | 8.81% | 7,799,518 | 123.31M | Sep 29, 2026 |
| RA Capital Management, L.P. | 8.69% | 7,692,750 | 121.62M | Jun 29, 2026 |
| Blackrock Inc. | 6.65% | 5,887,038 | 93.07M | Jun 29, 2026 |
| Samsara BioCapital, LLC | 6.63% | 5,871,018 | 92.82M | Jun 29, 2026 |
| FMR, LLC | 5.09% | 4,511,689 | 71.33M | Jun 29, 2026 |
| State Street Corporation | 4.68% | 4,141,636 | 65.48M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 2.83% | 2,502,854 | 39.57M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.22% | 1,968,124 | 31.12M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.79% | 1,584,493 | 25.05M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.66% | 1,468,689 | 23.22M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.33% | 1,180,000 | 18.66M | Sep 29, 2026 |
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 1.09% | 962,999 | 15.23M | Sep 29, 2026 |